|
Pemigatinib Clinical Trials
11 actively recruiting trials across 4 locations
Also known as: INCB054828, PEMAZYRE, Pemazyre, Pemazyre®
Pipeline
Phase 1: 2Phase 2: 9
Top Sponsors
- University of Utah1
- UNICANCER1
- Tianjin Medical University Cancer Institute and Hospital1
- The Netherlands Cancer Institute1
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine1
Indications
- Cancer11
- Solid Tumor, Miscellaneous1
- Neoplasia1
- Advanced Pancreatic Carcinoma1
- Tumors1
Other6 trials
Birmingham, Alabama2 trials
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ohio State University-Telemedicine
Phase 2
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
University of Alabama at Birmingham
Phase 2
Boston, Massachusetts1 trial
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
Phase 1
Portland, Oregon1 trial
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1
Salt Lake City, Utah1 trial
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Huntsman Cancer Institute at University of Utah
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.